文献速递儿科与产科急症消化、代谢与肾脏急症

鼻内氯胺酮用于儿童急性疼痛管理:系统评价与Meta分析

Intranasal ketamine for acute pain management in children: A systematic review and meta-analysis.
PubMed 文献 · Am J Emerg Med · 2020-06-01
一句话结论鼻内镇痛剂量氯胺酮与鼻内芬太尼在儿童急性疼痛中镇痛效果相似,但非严重不良事件风险更高(RR 2.00)。

该系统评价与Meta分析遵循PRISMA指南,检索PubMed、Embase和Scopus数据库截至2019年12月的随机对照试验,纳入4项试验共276名患者,比较鼻内氯胺酮与鼻内芬太尼用于儿童急性疼痛的疗效与安全性。结果显示,氯胺酮在干预后10-15分钟、30分钟和60分钟的疼痛评分降低与芬太尼相似(WMD分别为-1.42、0.40、-0.64,95%CI均跨0),补救镇痛率相似(RR 0.74,95%CI 0.44-1.25),但非严重不良事件风险更高(RR 2.00,95%CI 1.43-2.79),无患者出现严重不良事件或显著镇静。作者认为鼻内镇痛剂量氯胺酮可考虑作为阿片类药物的替代选择用于儿童急性疼痛管理。

要点

  • 鼻内氯胺酮与鼻内芬太尼在儿童急性疼痛中疼痛评分降低相似(10-15分钟WMD -1.42,95%CI -9.95至7.10;30分钟WMD 0.40,95%CI -6.29至7.10;60分钟WMD -0.64,95%CI -6.76至5.47)。
  • 氯胺酮组补救镇痛率与芬太尼相似(RR 0.74,95%CI 0.44至1.25)。
  • 氯胺酮组非严重不良事件风险高于芬太尼(RR 2.00,95%CI 1.43至2.79),无患者发生严重不良事件。
  • 芬太尼组发生1例严重不良事件(低血压),自行缓解;两组均无显著镇静。
  • 作者认为鼻内镇痛剂量氯胺酮可考虑作为阿片类药物替代用于儿童急性疼痛,取决于对非严重不良事件的耐受性和避免阿片类药物的意愿。

适用人群与场景

  • 儿童急性疼痛患者,纳入随机对照试验的4项研究共276名患者。

处置流程与药物剂量

  • 鼻内镇痛剂量氯胺酮可与鼻内芬太尼比较用于儿童急性疼痛;具体剂量、给药频次和目标值原文未提及。

研究设计与关键结果

  • 系统评价与Meta分析纳入4项随机对照试验共276名患者,比较鼻内氯胺酮与鼻内芬太尼用于儿童急性疼痛。
  • 疼痛评分从基线至干预后各时间点降低相似:10-15分钟WMD -1.42(95%CI -9.95至7.10);30分钟WMD 0.40(95%CI -6.29至7.10);60分钟WMD -0.64(95%CI -6.76至5.47)。
  • 补救镇痛率相似:RR 0.74(95%CI 0.44至1.25)。
  • 非严重不良事件风险:氯胺酮组高于芬太尼组(RR 2.00,95%CI 1.43至2.79);氯胺酮组无严重不良事件,芬太尼组发生1例严重不良事件(低血压)自行缓解;两组均无显著镇静。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入4项随机对照试验。
  • 检索PubMed、Embase和Scopus数据库从建库至2019年12月。
  • 采用随机效应模型评估加权均数差(WMD)和合并相对风险(RR)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为鼻内镇痛剂量氯胺酮可考虑作为阿片类药物替代用于儿童急性疼痛管理,其接受度取决于对非严重不良事件的耐受性和避免阿片类药物的意愿。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: To assess the efficacy and safety of intranasal analgesic-dose ketamine as compared to intranasal fentanyl for pediatric acute pain.

METHODS: A systematic review and meta-analysis was performed following the PRISMA guidelines. We searched PubMed, Embase, and Scopus databases for randomized controlled trials from inception to December 2019. We conducted meta-analysis with random-effects models to evaluate pain reduction, rescue analgesia, adverse events and sedation between intranasal ketamine and intranasal fentanyl. Random-effects models were used to estimate weighted mean differences (WMD) and pooled relative risks (RR).

RESULTS: A total of 546 studies were screened and 4 trials were included. In the meta-analysis of 4 studies including 276 patients, ketamine had similar reductions in pain scores from baseline to all post-intervention times (10 to 15 min: WMD -1.42, 95% CI -9.95 to 7.10; 30 min: WMD 0.40, 95% CI -6.29 to 7.10; 60 min: WMD -0.64, 95% CI -6.76 to 5.47). Ketamine was associated with similar rates of rescue analgesia (RR 0.74, 95% CI 0.44 to 1.25). Ketamine had a higher risk of non-serious adverse events (RR 2.00, 95% CI 1.43 to 2.79), and no patients receiving ketamine had a serious adverse event. There was one serious adverse event (hypotension) with fentanyl that self-resolved. No patients receiving either IN fentanyl or ketamine had significant sedation.

CONCLUSION: Intranasal analgesic-dose ketamine may be considered as an alternative to opioids for acute pain management in children. Its accepted use will depend on the tolerability of non-serious adverse events and the desire to avoid opioids.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Oliveira J E Silva L, Lee JY, Bellolio F, et al. Intranasal ketamine for acute pain management in children: A systematic review and meta-analysis. Am J Emerg Med. 2020. PMID: 32739857. doi:10.1016/j.ajem.2020.05.094

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。